Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Advances in stem cell-derived exosome therapy for radiation-induced skin injury

Kuo PJ., Rau CS., Hsieh CH.

Clinical Trial, published in Int J Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Surg (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40844299
PMCID
PMC12626575
DOI
10.1097/js9.0000000000003004
Citations
2

Abstract (original English)

Radiation-induced skin injury (RISI) represents a significant clinical challenge, affecting up to 95% of radiotherapy patients and often resulting in both acute and chronic complications that can severely impact quality of life. While conventional treatments show limited efficacy, stem cell-derived exosomes have emerged as a promising cell-free therapeutic approach. These nanoscale vesicles, which harbor bioactive chemicals derived from their progenitor stem cells, exhibit significant potential in facilitating tissue healing while mitigating the risks associated with cell-based therapies. This article reviews the therapeutic processes of exosomes produced from stem cells in the treatment of RISI, including their roles in reducing cellular senescence, promoting angiogenesis, modulating inflammation, and enhancing tissue regeneration. We examine 12 preclinical data and five clinical trials, assessing the efficacy of exosomes sourced from several stem cell types: mesenchymal, embryonic, and induced pluripotent stem cells. The review also addresses current challenges in exosome therapy development, including manufacturing scalability, characterization standards, and delivery optimization. Recent advances in clinical translation suggest that exosome-based treatments could revolutionize RISI management, offering a safer and potentially more effective alternative to existing therapies

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Stem CellsSkinAnimalsHumansRadiodermatitisRadiation InjuriesStem Cell TransplantationExosomes

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.